Nevro Corp. (NVRO)
NYSE: NVRO · Real-Time Price · USD
3.790
+0.200 (5.57%)
Dec 20, 2024, 4:00 PM EST - Market closed

Company Description

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally.

The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.

It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands.

In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors.

The company was incorporated in 2006 and is headquartered in Redwood City, California.

Nevro Corp.
Nevro logo
Country United States
Founded 2006
IPO Date Nov 6, 2014
Industry Medical Devices
Sector Healthcare
Employees 1,215
CEO Kevin Thornal

Contact Details

Address:
1800 Bridge Parkway
Redwood City, California 94065
United States
Phone 650 251 0005
Website nevro.com

Stock Details

Ticker Symbol NVRO
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001444380
CUSIP Number 64157F103
ISIN Number US64157F1030
Employer ID 56-2568057
SIC Code 3841

Key Executives

Name Position
Kevin R. Thornal President, Chief Executive Officer and Director
Roderick H. MacLeod Senior Vice President and Chief Financial Officer
Kashif Rashid J.D. Senior Vice President of Corporate Development and Chief Legal Officer
Greg Siller Senior Vice President and Chief Commercial Officer
Christofer Christoforou Senior Vice President and Chief Operating Officer
Angeline C. McCabe Vice President of Investor Relations and Corporate Communications
Shana D. Ross M.B.A. Senior Vice President and Chief Human Resources Officer
Dr. David Caraway M.D., Ph.D. Senior Vice President and Chief Medical Officer
Peter A. Socarras Vice President, General Counsel and Corporate Secretary

Latest SEC Filings

Date Type Title
Dec 4, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 8-K Current Report
Nov 12, 2024 10-Q Quarterly Report
Nov 8, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 22, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Sep 10, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Sep 10, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Aug 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals